Ground-breaking research on the microbiome — the collection of bacteria, fungi, and other microbes that live in the gut, on the skin, and within other human tissues — is creating new ways to treat disease. What started as a “bugs as drugs” approach to treatment is expanding to embrace the use of small molecules, biologics, phages, and engineered bacteria to modify the microbiome and prevent or alter disease progression.

Initially focused on the gastrointestinal tract, which was the origin of this burgeoning new field, manipulating the microbiome is now being viewed as a way to treat cancer, neurologic diseases such as Alzheimer’s and Parkinson’s disease, metabolic diseases like type 2 diabetes, and more.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy